Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUE NASDAQ:EXOZ NASDAQ:FRMM NASDAQ:HOWL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$21.29+5.9%$206.58$4.97▼$41.42$86.20M2.37494,307 shs34,964 shsEXOZeXoZymes$9.76+3.8%$9.28$7.08▼$18.40$82.67M2.854,144 shs14,633 shsFRMMForum Markets$4.72-3.4%$0.00$1.76▼$174.60$69.28M1.511.02 million shs144,879 shsHOWLWerewolf Therapeutics$0.45+7.2%$0.79$0.40▼$2.38$22.11M0.41460,233 shs461,569 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma-1.62%-20.65%-96.67%-92.16%-96.29%EXOZeXoZymes+1.60%-0.57%-10.14%+7.30%-36.96%FRMMForum Markets+17.59%+0.21%+20.79%+487,999,900.00%+487,999,900.00%HOWLWerewolf Therapeutics-3.56%-22.15%-53.31%-36.97%-60.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$21.29+5.9%$206.58$4.97▼$41.42$86.20M2.37494,307 shs34,964 shsEXOZeXoZymes$9.76+3.8%$9.28$7.08▼$18.40$82.67M2.854,144 shs14,633 shsFRMMForum Markets$4.72-3.4%$0.00$1.76▼$174.60$69.28M1.511.02 million shs144,879 shsHOWLWerewolf Therapeutics$0.45+7.2%$0.79$0.40▼$2.38$22.11M0.41460,233 shs461,569 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma-1.62%-20.65%-96.67%-92.16%-96.29%EXOZeXoZymes+1.60%-0.57%-10.14%+7.30%-36.96%FRMMForum Markets+17.59%+0.21%+20.79%+487,999,900.00%+487,999,900.00%HOWLWerewolf Therapeutics-3.56%-22.15%-53.31%-36.97%-60.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUECue Biopharma 1.00SellN/AN/AEXOZeXoZymes 1.00SellN/AN/AFRMMForum Markets 2.67Moderate Buy$10.00112.04% UpsideHOWLWerewolf Therapeutics 2.14Hold$3.75727.81% UpsideCurrent Analyst Ratings BreakdownLatest HOWL, CUE, EXOZ, and FRMM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/15/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$5.00 ➝ $9.005/11/2026FRMMForum Markets Loop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.005/11/2026FRMMForum Markets Clear StrSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026FRMMForum Markets BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSpeculative Buy$5.004/2/2026FRMMForum Markets Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)3/27/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUECue Biopharma$27.47M3.14N/AN/A$5.34 per share3.99EXOZeXoZymes$70K1,182.35N/AN/A$0.18 per share54.22FRMMForum Markets$6.55M10.47N/AN/A$11.57 per share0.41HOWLWerewolf Therapeutics$1.88M11.71N/AN/A$0.25 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUECue Biopharma-$26.60M-$5.58N/AN/AN/A-59.65%-98.30%-53.69%N/AEXOZeXoZymes-$9.16M-$1.14N/AN/AN/AN/A-220.63%-141.26%N/AFRMMForum Markets-$450.52M-$36.07N/AN/AN/AN/A-242.09%-135.46%N/AHOWLWerewolf Therapeutics-$60.82M-$1.24N/AN/AN/AN/A-208.23%-75.12%N/ALatest HOWL, CUE, EXOZ, and FRMM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CUECue Biopharma-$3.30-$1.08+$2.22-$1.08$2.50 million$5.69 million5/14/2026Q1 2026EXOZeXoZymesN/A-$0.28N/A-$0.28N/AN/A5/14/2026Q1 2026FRMMForum MarketsN/A-$3.64N/A-$3.58N/A$2.86 million5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A3/31/2026Q4 2025FRMMForum MarketsN/A-$12.14N/A-$12.24N/A$2.44 million3/30/2026Q4 2025EXOZeXoZymesN/A-$0.31N/A-$0.31N/AN/A3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCUECue BiopharmaN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AFRMMForum MarketsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUECue BiopharmaN/A3.573.57EXOZeXoZymes0.031.321.32FRMMForum Markets0.156.190.33HOWLWerewolf TherapeuticsN/A1.271.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUECue Biopharma35.04%EXOZeXoZymesN/AFRMMForum Markets4.07%HOWLWerewolf Therapeutics64.84%Insider OwnershipCompanyInsider OwnershipCUECue Biopharma1.82%EXOZeXoZymes72.41%FRMMForum Markets15.10%HOWLWerewolf Therapeutics23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUECue Biopharma604.05 million3.97 millionOptionableEXOZeXoZymes298.48 million2.34 millionN/AFRMMForum Markets714.54 million12.35 millionN/AHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableHOWL, CUE, EXOZ, and FRMM HeadlinesRecent News About These CompaniesLuke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockMay 21 at 8:23 AM | insidertrades.comHere's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn SituationMay 14, 2026 | finance.yahoo.comLuke Evnin Sells 33,948 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockMay 13, 2026 | insidertrades.comWerewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 79,086 SharesMay 8, 2026 | insidertrades.comWerewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | globenewswire.comWerewolf Therapeutics (NASDAQ:HOWL) Director Sells $34,533.36 in StockMay 5, 2026 | insidertrades.comInsider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 56,559 Shares of StockApril 30, 2026 | insidertrades.comWerewolf Therapeutics (HOWL) price target increased by 12.00% to 7.14April 28, 2026 | msn.comWerewolf Therapeutics Faces Nasdaq Delisting Risk After Falling Below $1 Minimum Bid PriceMarch 28, 2026 | tipranks.comWerewolf Therapeutics (HOWL) price target increased by 20.19% to 6.38March 27, 2026 | msn.comWerewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate UpdatesMarch 27, 2026 | globenewswire.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Announces Plan to Explore Strategic AlternativesFebruary 26, 2026 | finanznachrichten.deWerewolf Therapeutics Announces Plan to Explore Strategic AlternativesFebruary 24, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Medtronic (MDT), Elanco Animal Health (ELAN) and Werewolf Therapeutics (HOWL)February 18, 2026 | theglobeandmail.comWerewolf Therapeutics stock falls after announcing 64% workforce reductionFebruary 13, 2026 | investing.comWerewolf Therapeutics stock rises over 5% after hours on workforce reduction, including executivesFebruary 13, 2026 | msn.comWerewolf Therapeutics Receives Nasdaq Minimum Bid Price NoticeFebruary 6, 2026 | tipranks.comLuke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockJanuary 21, 2026 | insidertrades.comLuke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) StockJanuary 16, 2026 | insidertrades.comWerewolf Therapeutics (HOWL) price target decreased by 10.86% to 5.30January 15, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOWL, CUE, EXOZ, and FRMM Company DescriptionsCue Biopharma NASDAQ:CUE$21.28 +1.19 (+5.90%) As of 12:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.eXoZymes NASDAQ:EXOZ$9.76 +0.36 (+3.83%) As of 12:58 PM Eastern This is a fair market value price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.Forum Markets NASDAQ:FRMM$4.72 -0.16 (-3.36%) As of 01:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Forum Markets Inc is a digital asset platform modernizing capital markets through the tokenization of institutional-grade real-world assets on Ethereum. The company structures cash-generating assets on blockchain-based infrastructure to facilitate liquidity, investor access, and primary and secondary market activity. It combines traditional asset management practices with digital market infrastructure to support the origination, distribution, and trading of real-world assets.Werewolf Therapeutics NASDAQ:HOWL$0.45 +0.03 (+7.24%) As of 12:59 PM Eastern This is a fair market value price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Lowe's Finds Support at $215 After Q1 Earnings Sell-Off Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
